In this TOGA Podcast, Australian medical oncologist Dr Jenny Lee at Chris O’Brien Lifehouse, Sydney, is joined by medical oncologist Professor Nick Pavlakis, from Royal North Shore Hospital in Sydney and Lisa Briggs, Stage IV lung cancer survivor, Author, Osteopath and Exercise Physiologist who provides her own personal experience after being diagnosed with ALK+ non-small cell lung cancer in 2014. They discuss treatment of patients with non-small cell lung cancer with ALK mutations, the latest updates on ALK targeted therapies, the emergence of resistance, and how the choice of ALK inhibitor should be made between clinician and patient, taking into account potential side-effects, their management and the impact on the particular patient’s lifestyle. Support TOGA

Thank you for listening to Conversations in Lung Cancer Research. If you

enjoyed this episode, please rate and review us on Apple Podcasts or

Spotify.

---------------

Connect with TOGA

Attend an Event: https://thoraciconcology.org.au/events/

Become a Member: Join the TOGA community at

https://thoraciconcology.org.au/membership/

Donate: Support our research and treatment initiatives at

https://thoraciconcology.org.au/support-us/donate/

Follow Us

LinkedIn:

https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/

X (Twitter): https://x.com/TOGAANZ

Instagram: https://www.instagram.com/togaanz/

YouTube:  https://www.youtube.com/@Thoracic_Oncology

---------------

Acknowledgement of Country

The Thoracic Oncology Group of Australasia Limited acknowledges

Traditional Owners of Country throughout Australia and recognises the

continuing connection to lands, waters and communities. We pay our

respect to Aboriginal and Torres Strait cultures; and to Elders past and

present.